Jan Sigger joins Solstice’s Board of Directors

26th July 2021 – Jan Sigger, founder and former CEO of Quirem Medical, has joined the team at Solstice Pharmaceuticals as Chairman of the Board of Directors to provide the board with leadership and to harness the talents and energy contributed by each of the individual directors.

Read more

Solstice Awarded High Tech Fund support

21st July 2021 – We are pleased to announce that we have been granted support from the High Tech Fund. This financial support will enable us to establish our GMP pilot line for our UCA cartridges and accelerate our product development and clinical trajectory.

Read more

Parker Labs Leads Investment in Solstice Pharma’s Innovative Ultrasound Contrast Agent

2nd July 2021 – Solstice Pharmaceuticals has successfully completed its latest round of funding to further the clinical development of its innovative ultrasound contrast agent (UCA). The first-of-its-kind contrast agent uses unique microbubble technology that dramatically enhances image contrast, improves diagnostic accuracy and makes ultrasound more widely applicable for a wide range of diagnostic and therapeutic applications.

Read more